Protective Immune Responses to Dengue Virus Infection and Vaccines: Perspectives from the Field to the Bench by Scott B. Halstead & Simona Zompi
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EDITORIAL
published: 18 February 2015
doi: 10.3389/fimmu.2015.00075
Protective immune responses to dengue virus infection
and vaccines: perspectives from the field to the bench
Scott B. Halstead 1 and Simona Zompi 2,3*
1 International Vaccine Institution, Seoul, South Korea
2 Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, USA
3 Immunology and Global Health Consulting, Oakland, CA, USA
*Correspondence: simona@simonazompi.com
Edited and reviewed by:
Ian Marriott, University of North Carolina at Charlotte, USA
Keywords: dengue, antibodies,T cells, myeloid cells, NK cells, immunity, protection, vaccines
Dengue research is in turmoil following confusing efficacy reports
from large-scale phase III clinical studies on the lead candidate
tetravalent dengue vaccine (1–3). Within the context of the cur-
rent understanding of immunity in dengue or immunity to other
vaccines, the observed failures of protection cannot be adequately
explained. These results comprise the background to this review of
contemporary research on protective immunity in dengue, sum-
marized by Slifka (4). Studies on wild-type dengue virus (DENV)
infections of humans since World War II have revealed a consistent
pattern of cross-protection after a single DENV infection against
infection with a different DENV. Inapparent infections or mild dis-
ease accompany sequential DENV infections spaced at relatively
short intervals (<1.4–1.9 years), while overt and severe disease
accompany sequential infections at longer intervals. Grange et al.
provide an analytical review of inapparent DENV infections pub-
lished so far in the literature (5). It has been asked whether these
inapparent infections serve as a major reservoir for the sustained
infection of Aedes aegypti. Parameters of infection of A. aegypti by
feeding on humans with dengue illnesses described here by Car-
rington et al. are a model for research directed at answering this
question (6). An overview report by Endy (7) on the spectrum of
human responses to wild-type DENV infection, from inapparent
to hospitalized severe dengue, provides evidence that heterotypic
DENV plaque-reduction neutralizing antibodies do not predict
protection against a second DENV. This was the central feature
of the Sanofi tetravalent dengue vaccine trial in Thai children (1).
DENV 2 neutralizing antibodies uniformly were raised by three
doses of vaccine yet failed to protect against symptomatic DENV
2 infections (1).
A longitudinal study on human immune responses to wild-type
DENV infection describes how heterotypic immunity modulates
disease, including evidence that cellular immunity contributes
to protection (8). Weiskopf and Sette show that CD8+ T cells
contribute to protection against disease with second DENV infec-
tions by targeting epitopes on non-structural antigens (8). In the
Sanofi tetravalent chimeric vaccine, this T cell contribution may
be missing as DENV non-structural proteins are not present in the
vaccine, replaced by those of yellow fever (1–3). Studies on humans
and animal models, summarized by Petitdemange et al. (9), find
that antibody-dependent cell-mediated cytotoxicity (ADCC) and
natural killer (NK) cells contribute to controlling early-stage viral
infections. Since most human DENV infections are silent, NK
cell-mediated protection may dominate (9, 10). This possibility
is illustrated by observations from Cuba and Vietnam, reviewed
by Beltran and Lopez-Verges (10), where differential distribution
of alleles of the MHC-Class I chain-related genes A or B (MICA or
MICB) suggest that NK responses have been suppressed in those
individuals who developed severe disease. Cells of the immune
system, including dendritic cells (DCs), monocytes (Mo), and
macrophages (Mϕ) serve as hosts of DENV infection. Immature
DCs express DC-SIGN, a universal receptor for DENV. Immature
DCs evolve from blood Mo that have migrated into the skin. In a
mouse model, Schmid et al. show that immature DCs are initial
sites of infection and once infected become mature and migrate to
regional lymph nodes (11). Mature DCs lose DC-SIGN but gain
Fc receptors (FcRs) and can be infected efficiently by infectious
immune complexes. Different FcRs on Mo and Mϕ interact with
specific isotypes of IgG. When infectious DENV immune com-
plexes attach to Mo and Mϕ FcγRIIA a signal is sent suppressing
interferon (IFN) type I production leading to the enhanced virus
production (11).
A broad range of subhuman primate species are readily infected
with wild-type or attenuated DENV. But, monkeys do not respond
to infection with a disease mimicking the dengue vascular perme-
ability syndrome (DVPS). Nonetheless, immune responses and
protection to challenge in monkeys are closely similar to those
observed in humans. Sariol and White review the utility and limita-
tions of this animal model (12). Monkeys inoculated with tetrava-
lent Sanofi and Takeda live-attenuated chimeric vaccines revealed
the same dominance of DENV 4 and DENV 2-driven immune
responses and protection observed in humans, respectively. T cell
immune responses are scarcely studied in monkeys. In contrast, in
mouse models, as shown by Zellweger and Shresta (13), adoptive
transfer of T cells demonstrate the important contribution of the
T cell component to protection following a first or second DENV
infection. Mice lacking receptors to type I IFN, however, do have
a pathophysiological response closely similar to DVPS. In these
mice, suboptimal doses of DENV2 result in mild illness. In the
presence of enhancing concentrations of dengue antibodies, i.e.,
sub-neutralizing concentrations that induce antibody-dependent
enhancement or ADE, the same dose of DENV induces lethal
disease (13).
The review is completed by a description by Ambuel et al.
(14) of the successful immunization of cynomolgous monkeys
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using two doses of a DENV2 chimeric tetravalent vaccine given
at day 0 (rapid immunization strategy or RIS), as compared to
the traditional prime and boost given 2 months later. As evi-
dence of solid protection, when challenged with DENV 2, ani-
mals were protected against viremia with no boost in DENV
2 neutralizing antibodies, showing that the RIS induced a ster-
ilizing immunity (14). Another important feature of this trial
was the demonstration of T cell immunity to DENV 2 non-
structural proteins with collateral cross-reactive T cell immu-
nity to other DENV types (14). This original article shows
that RIS could be very useful in endemic areas to increase
compliance to vaccination schedules and reinforce the neces-
sity to study, in more detail, protective dengue-induced T cell
immunity.
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